WATCH | Raffaele Califano comments on the CASPIAN trial of front-line durvalumab plus chemotherapy in extensive-stage small-cell lung cancer, and puts the findings in context of the IMpower133 study of atezolizumab in the same setting (3:30).
Domachevsky et al. examine how positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography improves the staging and prognosis of patients with small cell lung cancer.
Zer A. et al. Eur Radiol 2016; 26: 3155. doi:10.1007/s00330-015-4132-2